We assessed changes in prostate lesions on serial magnetic resonance imaging (MRI) examinations in predicting biopsy results.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Fifty-five men undergoing two prostate MRI examinations ≥6months apart, followed by targeted biopsy, were included. Two radiologists assessed dominant lesions for an increase in size or suspicion score. Progression on MRI had lower sensitivity (23.5%-35.3%) and higher specificity (76.2%-90.5%) than prostate-specific antigen (PSA) velocity (sensitivity 70.6%, specificity 52.4%) for predicting positive biopsy. Highest accuracy was achieved by PSA velocity (63.6%) for positive biopsy, and by MRI (65.5%-72.7%) for Gleason >6 tumor. Findings support lesion progression on MRI serving as a basis for performing subsequent targeted biopsy.
Rosenkrantz AB, Rice SL, Wehrli NE, Deng FM, Taneja SS. Are you the author?
Department of Radiology, NYU Langone Medical Center, New York, NY, USA; Department of Urology, Division of Urologic Oncology, NYU Langone Medical Center, New York, NY, USA.
Reference: Clin Imaging. 2014 Oct 16. pii: S0899-7071(14)00230-7.